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Abstract
Introduction: Tropical spastic paraparesis/HTLV-1 associated myelopathy (TSP/HAM) is a disease caused by human T-cell 
lymphotropic virus type 1 (HTLV-I) that mainly infects CD4 T cells—for example, those of the CD4+CD25hiFOXP3+ [Treg] 
phenotype—where it inhibits forkhead box protein P3 (FOXP3) expression and promotes interferon-γ (IFN-γ) expression. 
However, the role it exerts on regulatory B cells (CD19+CD24hiCD38hi; Breg) is unknown. Methods: The frequencies of Treg 
and Breg cells was evaluated and the Th1 profiles were assessed in TSP/HAM patients and healthy control subjects. Results: 
Low percentages of Breg cells and high production of IFN-γ  were observed in patients compared to those in healthy control 
subjects. Conclusions: The low percentage of Breg cells in patients and the increase in the frequency of Th1 cells suggest an 
imbalance in the control of the inflammatory response that contributes to the immunopathogenesis of TSP/HAM.
Keywords: Tropical Spastic Paraparesis. HTLV-1 virus. Regulatory T cells. Regulatory B cells. Interferon-γ.
INTRODUCTION
Human T-cell lymphotropic virus type 1 (HTLV-1) was 
the first human retrovirus with oncogenic properties to be 
described1. It affects 5–10 million people worldwide, especially 
endemic regions such as Africa, Japan, the Caribbean, Iran, 
Australia, Peru, Chile, Brazil, and Colombia2. The incubation 
period of the virus ranges from years to decades and its 
transmission occurs through sexual contact, blood transfusions, 
needle sharing, and from mother to child through breast milk3. 
The virus is considered the causative agent of two potentially 
deadly diseases; namely, adult T-cell leukemia/lymphoma (ATL 
or ATLL) and tropical spastic paraparesis/HTLV-1 associated 
myelopathy (TSP/HAM). However, not all infected people 
develop these disorders; while an estimated 2–5% develop 
ATL and 0.25–2% develop TSP/HAM, the rest remain as 
asymptomatic carriers for the rest of their lives4.
In Colombia, the virus was first described in 1981 in the 
region of Tumaco (Nariño), with an estimated prevalence of 
7.5–10% in the Pacific Coastal Areas5. However, the virus is 
distributed to non-coastal areas such as Antioquia, Risaralda, 
Córdoba and Cundinamarca, among others. Between 2010 and 
2014, seven cases of HTLV-1 were reported in the regions of 
Nariño, Putumayo, Valle del Cauca, Risaralda and the Caribbean 
coast6. Despite the data shown above, epidemiological studies of 
the virus have not been carried out, which has limited knowledge 
of its prevalence in Colombia.
TSP/HAM is characterized by an upper motor neuron 
lesion and a slow and progressive axon-myelin degeneration 
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in the anterolateral cords of the thoracic and/or lumbar spinal 
cord. The associated clinical manifestations include decreased 
strength and spasticity in unilateral or bilateral lower limbs, 
back pain, and urinary symptoms (nocturia, increased in urinary 
frequency, incontinence, and erectile dysfunction). In addition, 
Patellar hyperreflexia with or without clonus and Babinski sign 
or substitutes may occur, with less sensory involvement and 
without affecting the upper limb or cognitive functions. This 
weakness increases progressively, and in most cases, there is 
a spastic or scissor gait, which can evolve to compromise the 
ability to walk3.
The events that trigger the development of TSP/HAM are 
not clearly known. Nevertheless, its development is associated 
with deficiencies in the immunoregulatory process. The virus 
infects CD4+CD25hiFOXP3+ Treg cells, activates the Tax viral 
protein, inhibits forkhead box protein P3 (FOXP3) expression, 
and promotes interferon gamma (IFN-γ) expression7. Therefore, 
infected cells acquire a Th1 type phenotype, becoming IFN-γ 
producing cells able to cross the blood-brain barrier and enter 
the central nervous system (CNS)8. The inflammatory response 
in the CNS is represented by TCD4+ cells, high production of 
IFN-γ, and TCD8+ cell recruitment specifically against the virus9.
Regulatory B-cells represent a subtype of cells that, like Treg 
cells, can inhibit the inflammatory response during infections 
and inflammation; however, they are altered in number and 
function during autoimmune diseases. B-cells with regulatory 
capacity have been described, with CD19+CD24hiCD38hi, 
CD19+CD24hiCD27+, and CD19+CD25hiCD71hi phenotypes 
found in blood and in sites of inflammation10. Breg cells with 
a CD19+CD24hiCD38hi phenotype inhibit Th1 differentiation 
in vitro11. They also inhibit the inflammatory response 
through mechanisms dependent on interleukin (IL)-10, IL-
35, and transforming growth factor beta (TGF-β), capable of 
controlling the induction and functioning of the Treg cells. 
In other autoimmune pathologies such as multiple sclerosis 
and rheumatoid arthritis, a deficiency in CD19+CD24hiCD38hi 
Breg cells has been observed, which leads to low production 
of IL-10 and deficiency in the control of Th1 differentiation12. 
However, the contribution of regulatory B-cells (Breg-
CD19+CD24hiCD38hi) in the pathogenesis of TSP/HAM has 
not yet been described.
Therefore, this work aimed to evaluate the frequency 
of circulating regulatory B-cells and their relationship 
to the frequency of TCD4+ and TCD8+ IFN-γ-producing 
cells in patients with TSP/HAM to provide information on 
immunoregulation mechanisms mediated by Breg cells in the 
pathogenesis of this disease.
METHODS
Study population
Nineteen patients over 18 years of age from the Neurology 
Service at San José University Hospital in Popayán, Cauca-
Colombia were studied. The included participants had 
neurological symptoms suspicious of TSP/HAM according 
to the treating neurologist, including spastic paraparesis, gait 
alterations, paresthesia, alterations in sensitivity, sensation 
of muscular weakness, and urinary incontinence, as well 
as hyperreflexia in the lower limbs, muscular hypertonia/
hypotonia and positive Babinski sign. These individuals 
underwent serology and western blot for HTLV-1, nine of which 
had positive findings and were selected for study inclusion. 
Additionally, nine healthy control subjects negative for HTLV-1 
by serology, human immunodeficiency virus (HIV)-negative 
and without acute or chronic conditions were included and were 
matched to patients according to age and sex. 
Ethical considerations
Each participant signed informed consent forms and 
completed a survey containing information on sociodemographic 
and neurological clinical data prior to providing a peripheral 
venous blood sample. All procedures were approved by the 
Ethics Committee of the University of Cauca.
Peripheral venous blood sampling
Peripheral blood sampling was performed by venous 
puncture in the forearm following biosafety protocols. This 
procedure was performed by trained personnel. Approximately 
15 mL of peripheral blood was taken from each participant 
in tubes with and without additives (Vacutainer, Beckton-
Dickinson, USA).
Detection of HTLV-1 virus infection
Enzyme-linked immunosorbent assays (ELISAs) were 
performed from the serum sample to detect the presence of 
anti-HTLV-1 antibodies, according to the manufacturer's 
recommendations (DIA.PRO, Milan, Italy). In positive samples, 
the diagnosis was confirmed by Western blot, according to the 
manufacturer's recommendations (Bio-Rad, Berkeley, CA).
Extraction of mononuclear cells from peripheral blood 
Peripheral blood mononuclear cells (PBMC) were separated 
by density gradient centrifugation with Ficoll-Hypaque 
(BioWhittaker, Walkersville, MD). Cell viability was evaluated 
using Trypan blue dye (Sigma Immunochemicals, St. Louis, 
MO, USA).
Phenotyping of Treg and Breg cell subpopulations
Approximately 1x106 PBMC were deposited into flow 
cytometry tubes (Falcon, Becton Dickinson, Oxnard, 
California). To identify Treg cells, surface labeling was 
performed with anti-CD4- fluorescein isothiocyanate (FITC) 
(clone: OKT4, eBioscience, San Diego, CA) and anti-CD25-
PECy5 (clone: BC96 eBioscience) antibodies. The cells were 
fixed with 2% paraformaldehyde, permeabilized with the 
fixation/permeabilization buffer solution (eBioscience, San 
Diego, CA) according to the manufacturer's recommendations, 
and subsequently incubated with anti-FOXP3-PE antibody 
(clone: 259D Biolegend). Finally, the cells were washed and 
resuspended in phosphate-buffered saline (PBS) and read 
on an Accuri C6 flow cytometer (BD Biosciences). For the 
phenotyping of the Breg cells, anti-CD19-PE (Beckman Coulter, 
Brea, CA, USA), anti-CD24-Alexa-fluor-647 (clone: ML5 
BioLegend) and anti-CD38-PECy5 (clone: HIT2 BioLegend) 
antibodies were added for 30 minutes at room temperature. 
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Subsequently, the cells were washed with PBS and fixed with 2% 
paraformaldehyde. The samples were read in a flow cytometer.
Evaluation of the intracellular production of IFN-γ 
For the detection of intracellular IFN-γ, 1x106 PBMC were 
stimulated with phorbol myristate acetate (PMA) (40 ng/mL) 
(InvivoGen, San Diego, CA, USA) and ionomycin (1 μg/mL) 
(Sigma, St. Louis, MO, USA) in the presence of 10 μg/mL 
Brefeldin A (Sigma, St. Louis, MO, USA) for six hours at 37°C 
and 5% CO2. At the end of the incubation period, the cells were 
labeled with anti-CD4-PECy5 (clone: RPA-T4) and anti-CD8-
PECy5 (clone: RPA-T8, BioLegend) antibodies for 30 minutes 
at room temperature, then washed with PBS and fixed with 2% 
paraformaldehyde. The cells were permeabilized with fixation/
permeabilization buffer solution (eBioscience, San Diego, CA) 
according to the manufacturer's recommendations and incubated 
with anti-IFN-γ -FITC antibody (clone 4S.B3, eBioscience) for 1.5 
hours at 4°C under darkness. Finally, the cells were washed with PBS 
and analyzed on an Accuri C6 flow cytometer (BD Biosciences).
Statistical analysis
The sociodemographic variables and clinical characteristics 
of the patients were analyzed by measures of central tendency 
and dispersion. The frequencies of Treg, Breg, and IFN-γ 
producing T-cells in the peripheral blood of TSP/HAM patients 
and control subjects were compared by Mann–Whitney U tests. 
The statistical analysis was performed in GraphPad Prism 
Software 5 (San Diego, CA, USA).
RESULTS
Socio-demographic and clinical characteristics
Among the nine confirmed patients with TSP/HAM, 55.6% 
were men and 44.4% were women, with ages ranging from 
32–79 years (median: 58.8 years), mainly from the rural area 
of the Department of Cauca (55.6%). As an epidemiological 
antecedent of the risk of acquiring HTLV-1 infection, six 
patients (75%) had received blood transfusion at least once in 
their lifetimes and none had been intravenous drug users or had 
had homosexual relationships prior to the study. According to 
the neurological clinical examinations, the most frequent signs 
and symptoms were paraparesis of the lower limbs, paresthesia, 
gait alterations and hypotonia, which were present in 55.6% of 
the cases. Babinski sign and hyperreflexia in the lower limbs 
were present in 66.6% of the cases. Urological symptoms such 
as urinary incontinence and erectile dysfunction occurred in 
88.8% of patients (Table 1).
Percentage of CD4+CD25hi and CD4+CD25hiFOXP3+ cells 
in TSP/HAM patients and control subjects 
Cells with a regulatory function capable of suppressing 
the inflammatory response are altered in number and function 
in different chronic inflammatory and autoimmune diseases. 
These cells are identified by the high expression of CD25 in 
addition to the expression of the FOXP3 transcription factor13, 
which is considered the best lineage marker in this cellular 
subpopulation. In the present study, the frequencies of cells 
with CD4+CD25hi and CD4+CD25hiFOXP3+ phenotypes in 
peripheral blood of TSP/HAM patients and control subjects were 
evaluated by flow cytometry. The analysis of the frequencies 
of these subpopulations showed no significant differences 
between TSP/HAM patients and control subjects, although an 
increasing tendency of these two subpopulations was observed 
in the patient group. The median percentages of CD4+CD25hi 
cells in the patients and control groups were 2.3 (interquartile 
range [IQR] 1.25–5.1) and 1.58 (IQR 1.06-2.5), respectively. In 
contrast, the percentages of CD4+CD25hiFOXP3+ cells were 3.38 
(IQR 2.26–3.48) and 2.5 (1.52–3.44), respectively (Figure 1).
Percentages of Breg cells (CD19+CD24hiCD38hi) in TSP/
HAM patients and control subjects
Under normal conditions, Breg cells are characterized by their 
inhibition of the inflammatory response; however, the number 
of these cells is altered in autoimmune diseases. In this study, 
the median percentage of Breg cells with CD19+CD24hiCD38hi 
phenotype was significantly lower in patients with TSP/HAM 
compared to that in the control subjects (2.9 [IQR1.9–2.4] vs. 
8.5 [IQR 4.4–11.2], p <0.05) (Figure 2). This result suggests 
that within this pathology there are alterations in the number 
of Breg cells (CD19+CD24 hiCD38 hi) which contribute to the 
control deficiency of the inflammatory response of the disease.
Percentages of CD4+ and CD8+ IFN-γ  producing cells in 
TSP/HAM patients and control subjects
Previous studies have shown an increase in the frequency 
of IFN-γ  producing cells in TSP/HAM patients7. In the present 
study, quantification the percentages of CD4+ and CD8+ IFN-γ 
-producing cells showed an increased percentage in patients 
compared to that in the control subjects (p<0.01). The median 
percentages of T CD4+IFN-γ+ T cells in the patients and 
controls were 9.7% (IQR 2.9–23.7) and 0.78% (IQR 0.28–4.1), 
respectively. Similar results were observed for CD8+IFN-γ+ T 
cells, with medians of 16.1% (IQR 4.9–47.3) and 1.6% (IQR 
1.5–8.04), respectively (p <0.05) (Figure 3).
Ratios of the percentages of CD4+IFN-γ +/
CD19+CD24hiCD38hi and CD8+IFN-γ +/
CD19+CD24hiCD38hi cells in TSP/HAM  
patients and control subjects
Considering the low percentages of Breg cells (CD19+CD24hi 
CD38hi) and high percentages of CD4+ and CD8+ IFN-γ producing 
cells TSP/HAM patients, the coefficient of the ratio of CD4+IFN-γ+/
CD19+CD24hiCD38hi and CD8+IFN-γ+/CD19+CD24hi CD38hi 
cells was calculated between patients and control subjects. The 
coefficient was higher in patients than that in control subjects for 
the ratio of CD4+IFN-γ+/CD19+CD24hi CD38hi, (median: [IQR] 
2.7 [0.9–11.2] in patients vs median: [IQR] 0.07 [0.03–1.1] in 
control subjects; p <0.05) and for the ratio of CD8+IFN-γ +/
CD19+CD24hi CD38hi, (median: [IQR] 5.2 [1.4–18.7]) in patients 
vs median: [IQR] 0.28 [0.13–1.2] in control subjects; p <0.01) 
(Figure 4). This inverse relationship suggests an expansion of 
IFN-γ  producing cells and a reduction in the number of Breg 
cells (CD19+CD24hiCD38hi) in TSP/HAM.
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TABLE 1: Sociodemographic and clinical characteristics of patients with tropical spastic paraparesis/HTLV-1 associated myelopathy (TSP/HAM) and in 
control subjects.
  
TSP/HAM Control subjects
(n=9) n (%) (n=9) n (%)
Male 5 (55.6) 5 (55.6)
Female 4 (44.4) 4 (44.4))
Median age (range) 58.8 (32-79) 57.6(31-78)
Residence Urban 4(44.4) 8(88.8)
Rural 5 (55.6) 1 (11.1)
* BMI (kg/m2) Normal 6 (66.7) 4 (44.4)
Overweight 3(33.3) 5(55.5)
Breastfeeding background 4(44.4) 8 (88.8)
Blood donation background 3(33.3) 4 (44.4)
Transfusion background 6 (75) 0(0)
Neurological symptoms LL spastic paraparesia 5 (55.6)
LlLparesthesia ** 5 (55.6)
Gait alterations 5 (55.6)
Babinski sign 6 (66.6)
LL normotonia 2 (22.2)
LL hypertonia 1 (11.1)
LL hypotonia 5 (55.6)
LL hyporeflexia 1 (11.1)
LL hypereflexia with or without clonus 6 (66.6)
Cerebellar signs 2 (22.2)
Alterations of cranial pairs 1 (11.1)
Urological symptoms Incontinence 5 (55.6)
 Erectile dysfunction 3 (33.3)  
*BMI: body mass index; **LL: lower limbs. Obesity and low weight were examined in patients and control subjects in cases in which no patient with these 
characteristics was found.
DISCUSSION
The present work evaluated the percentages of Treg 
(CD4+CD25hi and CD4+CD25hiFOXP3+), Breg (CD19+CD24hi 
CD38hi), and CD4 and CD8 IFN-γ -producing cells in nine patients 
with TSP/HAM, compared to those in healthy control subjects. 
Regarding sociodemographic data, the presentation of the 
disease at older ages (median age 58.8 years) could be associated 
with the natural evolution of the virus and the chronicity of 
infection that is consistent with what has been reported in other 
studies14-16. Intravenous drug use, homosexual relations, and 
blood transfusions have been described as epidemiological 
risk factors for acquiring HTLV-1 infection. From these, only 
a background history of blood transfusions was present among 
the patients and could have been the main route of transmission 
in these cases.
TSP/HAM patients with neurological characteristics typical 
of the disease associated with HTLV-1 infection initially present 
sensory/motor manifestations (hyperreflexia, hypertonia), 
urological manifestations (urinary incontinence, sexual 
dysfunction, neurogenic bladder), which evolve to progressive 
spastic paraparesis in the lower limbs, gait alterations, and 
generalized pyramidal signs (Babinski sign and substitutes, 
Hoffman's sign)17,18. In our study, there was a greater tendency 
for patients to develop this type of symptomatology. These 
findings correlate with prior reports in the literature in which 
patellar hyperreflexia and Babinski sign may be present in 
100% and 90–100% of patients infected with the virus18,19. The 
other frequent symptoms in this group of patients included 
urological symptoms, reaffirming the importance of looking 
for this symptomatology in all patients in whom infection with 
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FIGURE 1: Quantification of the frequency of circulating Treg cells. Representative graph showing the flow cytometry analysis strategy for CD4+CD25hi 
and CD4+CD25hiFOXP3+cellular subpopulations (A). Dot graphs showing the frequency of CD4+CD25hi cells (B) and CD4+CD25hiFOXP3+ cells (C) in nine 
TSP/HAM patients and nine healthy control subjects. Each dot represents individual values in each group, while the horizontal lines indicate the median 
and standard errors. The data were analyzed using Mann–Whitney U tests. p = ns.
FIGURE 2: Quantification and percentage of Breg cells with CD19+CD24hiCD38hi phenotype in peripheral blood 
mononuclear cells. A representative flow cytometry graph of B cells (CD19+) corresponding to the CD19+CD24hiCD38hi 
subpopulations (A). The dot chart shows the frequency of Breg cells (CD19+CD24hiCD38hi) in nine TSP/HAM patients 
and control subjects. Each dot represents individual values in each group, while the horizontal lines indicate the 
median and standard errors. The data were analyzed using Mann–Whitney U tests. ** = p <0.01.
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FIGURE 4: Percentage ratios of CD4+IFN-γ+/CD19+CD24hiCD38hi (A) and CD8+IFN-γ+/CD19+CD24hiCD38hi (B) cells in nine patients 
with TSP/HAM and nine healthy control subjects. Each dot represents an individual value in each group, while the horizontal lines indicate 
the median and standard errors. The data were analyzed using Mann–Whitney U tests with p <0.05 (*) and p <0.01 (**).
FIGURE 3: Quantification of the frequency of CD4+ and CD8+ lymphocytes producing interferon-gamma (IFN-γ). Representative flow 
cytometry graph of T CD4+ (A) and CD8+ (B) subpopulations of IFN-γ producing cells. The dot charts show the frequency of CD4+ (C) and CD8+ 
(D) IFN-γ producing cells in nine TSP/HAM patients and nine healthy control subjects. Each dot represents an individual value in each group, while 
the horizontal lines indicate the median and standard errors. The data were analyzed using Mann–Whitney U tests. ** = p <0.01, * = p <0.05.
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HTLV-1 is suspected, or in those patients who consult for urinary 
symptoms with an unclear origin. This is important given that 
these types of alterations can become a silent problem and occur 
many years before the manifestation of the spastic paraparesis 
associated with HTLV-120. It is noteworthy that of the 19 patients 
suspected of TSP/HAM, only nine received confirmation of 
the disease, reaffirming the similarity between the clinical 
presentation of TSP/HAM and a variety of neurological diseases, 
especially those associated with motor neuron disorders. 
Therefore, according to each patient’s clinical context, a call is 
made to consider HTLV-1 infection as an alternative diagnosis 
when other, more common diseases have been ruled out since 
this diagnosis could alter the patient prognosis and management.
Evaluation of the cells with regulatory function in the nine 
patients with TSP/HAM showed no significant difference in Treg 
cell populations with CD4+CD25hi and CD4+CD25hiFOXP3+ 
phenotypes from those in the control subjects. These results 
were discordant with those reported in the literature showing 
decreased expression of FOXP3-positive cells in patients with 
TSP/HAM7,21,22. This difference could be due to the fact that 
CD4+CD25hiFOXP3+ cells were quantified in this study from the 
total number of mononuclear cells isolated from patients and 
control subjects, without discriminating if they were infected, 
which leads us to suspect that the virus affects the expression of 
FOXP3 directly in infected cells, without directly or indirectly 
altering uninfected cells of the same phenotype.
Alterations in the number and function of Breg cells 
have been described in other chronic inflammatory and 
autoimmune diseases. To our knowledge, the present study is 
the first to describe the frequency of circulating Breg cells with 
CD19+CD24hiCD38hi phenotype in TSP/HAM pathology. The 
reduced frequency of these cells in TSP/HAM patients compared 
to those in healthy control subjects is similar to the results 
reported for this cell lineage in other autoimmune inflammatory 
pathologies such as systemic lupus erythematosus11 and 
multiple sclerosis23. The reduction of Breg cells in patients with 
TSP/HAM could be associated with defects in the regulation 
of Th1 type cells, which has been demonstrated to trigger 
a physiological process which results in tissue damage 
caused mainly by an increase in proinflammatory cytokines 
such as IFN-γ7.
Evaluation of the production of IFN-γ  in TCD4+ and TCD8+ 
lymphocytes in patients and healthy control subjects showed 
a significant increase in patients; consistent with that reported 
in the literature showing IFN-γ-producing cells proliferation 
by impairment of Treg cells to regulate Th1 cell differentiation 
in TSP/HAM21. Other phenomena that explain Th1 expansion 
include a cellular plasticity phenomenon described in 2017 
by Yamano and Coler-Reilly, who demonstrated reduced 
expression of regulatory T-cells with CD4+CD25hiFOXP3+ 
phenotype infected by HTLV-1 as a consequence of viral Tax 
protein activation. This protein activates the expression of the 
transcription factor T-bet, whose main function is to decrease 
the expression of FOXP3 and to increase IFN-γ production, 
resulting in cellular plasticity in which the cells are converted 
to a Th1-like phenotype23,24.
Since a high production of IFN-γ  in CD4+ and CD8+ cells 
and a low percentage of Breg cells (CD19+CD24hiCD38hi) 
were observed in patients with TSP/HAM, we compared the 
percentage ratio of CD4+IFN-γ and CD8+IFN-γ  cells to the 
percentage of Breg cells. The results showed a significant 
difference in both cases. Thus, the coefficient of the relationship 
between IFN-γ-producing and Breg cells was higher in 
patients with TSP/HAM compared to that in healthy control 
subjects. Therefore, patients with TSP/HAM had a greater 
number of IFN-γ-producing cells while the number of Breg 
cells decreased, which could be associated with defects in the 
regulation of Th1-type cells and may be related to inflammatory 
processes mediated by IFN-γ, which in turn mediates tissue 
damage.
To our knowledge, the present study is the first to 
demonstrate the role of Breg cells (CD19+CD24hiCD38hi) 
in the pathophysiology of TSP/HAM. The decrease of this 
cellular phenotype in the pathology is related to the deficiency 
of the regulatory processes of the immune system, which, 
combined with the effect exerted by the virus on Treg cells, 
triggers a predominance of Th1 cells, which is associated with 
characteristic tissue damage. As there are currently no accurate 
treatment for HTLV-1 infection nor TSP/HAM, the present 
results offer another perspective in the search for new targets; 
more specifically, for the application of innovative treatments 
focused on the phenotypes described to improve the immune 
regulatory process and prevent tissue damage associated with 
TSP/HAM. 
One of the limitations of the study was the small number of 
patients evaluated; despite this, considering the low prevalence 
of the disease and the difficulty in clearly identifying patients 
infected with the virus, the results presented here contribute 
significantly to the study of the immunopathogenesis of the 
disease. Additionally, future studies that directly evaluate the 
function of regulatory cells in infected cells would complement 
the data presented here.
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